1. 347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial. (10th December 2020) Authors: Winer, Ira; Gilbert, Lucy; Vaishampayan, Ulka; Rosen, Seth; Hoimes, Christopher; Muzaffar, Jameel; Spreafico, Anna; McDermott, David; Chu, Quincy; Dumas, Olivier; Chauhan, Aman; Chaudhry, Arvind; Tomczak, Piotr; Boni, Valentina; Bruno, Debora; Curtis, Kelly; Wang, Yan; Dorn, Elizabeth; Rege, Jess... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A211 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2. (10th December 2020) Authors: Powderly, John; Carthon, Bradley; Ernstoff, Marc; Olszanski, Anthony; Wrangle, John; Shields, Anthony; Piha-Paul, Sarina; Curtis, Kelly; Bidollari, Ilda; Du, Yangchun; Sun, Lei; Putiri, Emily; Wang, Yan; Losey, Heather; Dezube, Bruce; Dezube, Bruce; Vaishampayan, Ulka Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2. (9th November 2020) Authors: Powderly, John; Carthon, Bradley; Ernstoff, Marc; Olszanski, Anthony; Wrangle, John; Shields, Anthony; Piha-Paul, Sarina; Curtis, Kelly; Bidollari, Ilda; Du, Yangchun; Sun, Lei; Putiri, Emily; Wang, Yan; Losey, Heather; Dezube, Bruce; Dezube, Bruce; Vaishampayan, Ulka Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A398 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil. (August 2021) Authors: Kelly, Deanna L.; Claxton, Amy; Bidollari, Ilda; Du, Yangchun Journal: Psychiatry research Issue: Volume 302(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Challenges of post‐authorization safety studies: Lessons learned and results of a French study of fentanyl buccal tablet. Issue 5 (13th October 2017) Authors: Gavrielov‐Yusim, Natalie; Bidollari, Ilda; Kaplan, Sigal; Bartov, Netta Journal: Pharmacoepidemiology and drug safety Issue: Volume 27:Issue 5(2018) Page Start: 457 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. (November 2020) Authors: Naismith, Robert T; Wolinsky, Jerry S; Wundes, Annette; LaGanke, Christopher; Arnold, Douglas L; Obradovic, Dragana; Freedman, Mark S; Gudesblatt, Mark; Ziemssen, Tjalf; Kandinov, Boris; Bidollari, Ilda; Lopez-Bresnahan, Maria; Nangia, Narinder; Rezendes, David; Yang, Lili; Chen, Hailu; Liu, Shif... Journal: Multiple sclerosis Issue: Volume 26:Number 13(2020) Page Start: 1729 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. F2. CHANGE IN PROLACTIN AND SEXUAL SIDE EFFECTS IN PATIENTS WITH SCHIZOPHRENIA WHO SWITCHED FROM PALIPERIDONE PALMITATE OR RISPERIDONE LONG-ACTING INJECTION TO ARIPIPRAZOLE LAUROXIL. (9th April 2019) Authors: Kelly, Deanna; Claxton, Amy; Bidollari, Ilda; Du, Yangchun Journal: Schizophrenia bulletin Issue: Volume 45(2019)Supplement 2 Page Start: S255 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Safety and Tolerability of Aripiprazole Lauroxil 2-Month Formulation With 1-Day Initiation for Treatment of Schizophrenia in the ALPINE Study. (April 2021) Authors: Bidollari, Ilda; Vasios, Alexa; Claxton, Amy Journal: CNS spectrums Issue: Volume 26:Number 2(2021) Page Start: 158 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗